The study included sub-cohorts for PD-L1 22C3, PD-L1 28.8, ER, PR and HER2 where status of markers (positive or negative) was previously established via immunohistochemistry (IHC) of tumor tissue obtained by invasive biopsy. The gene discussed is CD274; the disease is neoplasm.